Tags

Type your tag names separated by a space and hit enter

Splenic marginal zone lymphoma: Clinical clustering of immunoglobulin heavy chain repertoires.
Blood Cells Mol Dis. 2009 May-Jun; 42(3):286-91.BC

Abstract

Immunoglobulin gene usage and somatic mutation patterns were studied in 59 patients with splenic marginal zone lymphoma and were correlated with clinical characteristics. Fifty-nine IGHV rearrangements were amplified. IGHV1, IGHV3, and IGHV4 subgroups accounted for 30%, 56%, and 14% of sequences, respectively. IGHV genes most frequently used were IGHV1-2 (n=12), IGHV3-23 (n=15), IGHV3-30 (n=7) and IGHV4-34 (n=5). IGHV was unmutated in 25%. Villous lymphocytes >10% were detected in 50% of patients belonging to the IGHV1-2 group, in 21% of the IGHV3-23 group, and in no patient of the IGHV3-30 group (p=0.05). Liver involvement was present in 50% of the IGHV3-30 group, in 9% of the IGHV3-23 group, and in no patient of the IGHV1-2 group (p=0.04). HCV-serology was positive in 50% of the IGHV3-30 group, in 7% of the IGHV3-23 group, and in 17% of the IGHV1-2 group (p=0.04). The proportion of intermediate and high risk patients according to the SMZL score was higher in the unmutated respect to the mutated group (69% vs 32%, p=0.05). In conclusion, IGHV rearrangement analysis in splenic marginal zone B-cell lymphoma reveals a non-random preference for use of IGHV1-2, IGHV3-23 and IGHV3-30 genes, whose presence differs according to clinical features and prognostic category.

Authors+Show Affiliations

Division of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia - Viale C. Golgi 19, 27100 Pavia, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

19250848

Citation

Arcaini, Luca, et al. "Splenic Marginal Zone Lymphoma: Clinical Clustering of Immunoglobulin Heavy Chain Repertoires." Blood Cells, Molecules & Diseases, vol. 42, no. 3, 2009, pp. 286-91.
Arcaini L, Zibellini S, Passamonti F, et al. Splenic marginal zone lymphoma: Clinical clustering of immunoglobulin heavy chain repertoires. Blood Cells Mol Dis. 2009;42(3):286-91.
Arcaini, L., Zibellini, S., Passamonti, F., Rattotti, S., Lucioni, M., Invernizzi, R., Merli, M., Rizzi, S., Boveri, E., Rumi, E., Astori, C., Picone, C., Varettoni, M., Pascutto, C., Paulli, M., & Lazzarino, M. (2009). Splenic marginal zone lymphoma: Clinical clustering of immunoglobulin heavy chain repertoires. Blood Cells, Molecules & Diseases, 42(3), 286-91. https://doi.org/10.1016/j.bcmd.2009.01.004
Arcaini L, et al. Splenic Marginal Zone Lymphoma: Clinical Clustering of Immunoglobulin Heavy Chain Repertoires. Blood Cells Mol Dis. 2009 May-Jun;42(3):286-91. PubMed PMID: 19250848.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Splenic marginal zone lymphoma: Clinical clustering of immunoglobulin heavy chain repertoires. AU - Arcaini,Luca, AU - Zibellini,Silvia, AU - Passamonti,Francesco, AU - Rattotti,Sara, AU - Lucioni,Marco, AU - Invernizzi,Rosangela, AU - Merli,Michele, AU - Rizzi,Silvia, AU - Boveri,Emanuela, AU - Rumi,Elisa, AU - Astori,Cesare, AU - Picone,Cristina, AU - Varettoni,Marzia, AU - Pascutto,Cristiana, AU - Paulli,Marco, AU - Lazzarino,Mario, Y1 - 2009/02/27/ PY - 2009/01/15/received PY - 2009/01/20/revised PY - 2009/01/20/accepted PY - 2009/3/3/entrez PY - 2009/3/3/pubmed PY - 2009/8/21/medline SP - 286 EP - 91 JF - Blood cells, molecules & diseases JO - Blood Cells Mol. Dis. VL - 42 IS - 3 N2 - Immunoglobulin gene usage and somatic mutation patterns were studied in 59 patients with splenic marginal zone lymphoma and were correlated with clinical characteristics. Fifty-nine IGHV rearrangements were amplified. IGHV1, IGHV3, and IGHV4 subgroups accounted for 30%, 56%, and 14% of sequences, respectively. IGHV genes most frequently used were IGHV1-2 (n=12), IGHV3-23 (n=15), IGHV3-30 (n=7) and IGHV4-34 (n=5). IGHV was unmutated in 25%. Villous lymphocytes >10% were detected in 50% of patients belonging to the IGHV1-2 group, in 21% of the IGHV3-23 group, and in no patient of the IGHV3-30 group (p=0.05). Liver involvement was present in 50% of the IGHV3-30 group, in 9% of the IGHV3-23 group, and in no patient of the IGHV1-2 group (p=0.04). HCV-serology was positive in 50% of the IGHV3-30 group, in 7% of the IGHV3-23 group, and in 17% of the IGHV1-2 group (p=0.04). The proportion of intermediate and high risk patients according to the SMZL score was higher in the unmutated respect to the mutated group (69% vs 32%, p=0.05). In conclusion, IGHV rearrangement analysis in splenic marginal zone B-cell lymphoma reveals a non-random preference for use of IGHV1-2, IGHV3-23 and IGHV3-30 genes, whose presence differs according to clinical features and prognostic category. SN - 1096-0961 UR - https://www.unboundmedicine.com/medline/citation/19250848/Splenic_marginal_zone_lymphoma:_Clinical_clustering_of_immunoglobulin_heavy_chain_repertoires_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1079-9796(09)00013-8 DB - PRIME DP - Unbound Medicine ER -